ALEX² Sensitization Profiles and Documented Allergen Immunotherapy Recommendations in Adults with Allergic Rhinitis or Rhinoconjunctivitis

Imagine walking into a doctor's office with a nose that runs, eyes that itch, and a throat that feels perpetually scratchy. For many people, these are the familiar, frustrating signs of an allergic reaction, a condition where the body's immune system mistakenly identifies harmless substances like pollen or dust as dangerous invaders. To figure out exactly what is triggering this reaction, doctors often use two main tools. The first is a skin prick test, where tiny drops of potential allergens are placed on the skin to see if a small bump appears, indicating a reaction. The second, a newer and more detailed approach, is a blood test that looks for specific antibodies the body has made against individual molecules within those allergens. While the skin test gives a broad picture, the blood test acts like a high-resolution map, showing exactly which parts of the pollen or dust the immune system is attacking. This distinction matters deeply because it helps doctors decide whether a patient should undergo immunotherapy, a treatment that gradually trains the immune system to tolerate the allergen, rather than just managing symptoms with medication.

In a recent study conducted in Bucharest, Romania, a team of researchers set out to see how these two testing methods work together in real-world patients suffering from allergic rhinitis and rhinoconjunctivitis. They focused on a specific, advanced blood test called ALEX², which can detect sensitivity to a vast array of allergens at once, ranging from ragweed and grass to house dust mites and animal dander. The researchers reviewed the medical records of one hundred adults who had visited an ear, nose, and throat clinic and an allergy clinic between August 2025 and July 2026. These patients had already been tested with the ALEX² system, and the team wanted to understand the patterns of their sensitivities, how those patterns matched up with their skin test results, and how this information influenced the doctors' decisions about immunotherapy.

The study revealed that allergic reactions in this group were rarely simple. While some patients reacted to just one type of pollen, a majority, specifically fifty-seven percent, were sensitive to at least two completely different sources of allergens, a condition known as polysensitization. The most common triggers found were ragweed, which affected forty-one percent of the patients, followed by grass pollen at thirty-six percent and house dust mites at twenty-five percent. This mix of seasonal and year-round triggers is typical for people living in regions where ragweed is prevalent, such as the Pannonian Plain and neighboring areas of Romania. The researchers also noted that many patients had symptoms that appeared only during specific seasons, while others suffered year-round, often with additional issues like asthma or nasal polyps.

When the team compared the results of the advanced blood tests with the traditional skin prick tests, they found a high level of agreement for the allergens that were actually tested. Among the patients who had both tests done, the blood test confirmed the skin test results in nearly all cases for grass, ragweed, and cat dander. However, the study also highlighted a crucial limitation: the blood test did not always agree with the skin test for every single allergen, and the researchers could not determine which test was universally better because they only looked at cases where the skin test was already positive. In a small number of instances, a patient had a positive skin test for a specific allergen but a negative result on the corresponding part of the blood test. This suggests that while the blood test is powerful, it is not a perfect replacement for the skin test, and doctors must look at the whole picture of a patient's history and symptoms to make sense of the data.

The most significant part of the study concerned how these test results guided treatment. Allergen immunotherapy was recommended for thirty-one percent of the patients, with fifteen percent either starting the treatment or having a plan in place. The most common target for this treatment was ragweed, which was chosen as the primary allergen for thirty-five percent of the patients who had a specific treatment goal. House dust mites were the next most frequent target. The researchers observed that patients who were sensitive to house dust mites were more likely to be recommended for immunotherapy than those who were not. They also found that patients who were sensitive to multiple allergens tended to have higher levels of total antibodies in their blood, suggesting a more active immune response, though this did not automatically mean they were sicker.

Despite these detailed findings, the authors were careful to state what their study could not prove. They emphasized that their work was a look back at existing records, not a new experiment designed to test the effectiveness of the treatments. Therefore, they could not say for certain that the advanced blood test alone changed the doctors' minds or that it was the sole reason immunotherapy was chosen. The decisions were made by looking at the blood test results alongside the patient's history, their skin test results, and their physical examination. The study also noted that while the blood test helped identify complex patterns of sensitivity, it did not always clarify which specific allergen was causing the symptoms, especially when a patient reacted to many different things at once. In such cases, doctors had to use their judgment to decide which allergen was the most likely culprit and whether immunotherapy would be safe and effective.

Ultimately, this research provides a clear snapshot of how modern allergy testing is being used in a busy clinical setting. It shows that while advanced molecular testing can reveal a complex web of sensitivities, it works best when combined with traditional methods and a careful look at the patient's life and symptoms. The study confirms that ragweed is a major driver of seasonal allergies in this region and that immunotherapy is a viable option for a significant portion of patients, particularly those with clear targets like ragweed or dust mites. However, it also serves as a reminder that technology alone does not solve the puzzle of allergy; the human element of interpreting these results within the context of a person's unique health history remains the most critical step in finding the right path to relief.